Overview

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Status:
Not yet recruiting

Trial end date:
2026-02-16

Target enrollment:

Participant gender:

Summary

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Fulvestrant